Overview

Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)

Status:
Completed
Trial end date:
2020-04-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple-ascending doses of ARO-HBV in healthy adult volunteers and participants with hepatitis B virus (HBV).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Arrowhead Pharmaceuticals